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Abstract 
Background: Non-human primates, such as the rhesus macaques, are the preferred model for down-selecting 
human malaria vaccine formulations, but the rhesus model is expensive and does not allow for direct efficacy testing 
of human malaria vaccines. Transgenic rodent parasites expressing genes of human Plasmodium are now routinely 
used for efficacy studies of human malaria vaccines. Mice have however rarely predicted success in human malaria 
trials and there is scepticism whether mouse studies alone are sufficient to move a vaccine candidate into the clinic.
Methods: A comparison of immunogenicity, fine-specificity and functional activity of two Alum-adjuvanted Plasmo-
dium falciparum circumsporozoite protein (CSP)-based vaccines was conducted in mouse and rhesus models. One 
vaccine was a soluble recombinant protein (CSP) and the other was the same CSP covalently conjugated to the Qβ 
phage particle (Qβ-CSP).
Results: Mice showed different kinetics of antibody responses and different sensitivity to the NANP-repeat and 
N-terminal epitopes as compared to rhesus. While mice failed to discern differences between the protective efficacy 
of CSP versus Qβ-CSP vaccine following direct challenge with transgenic Plasmodium berghei parasites, rhesus serum 
from the Qβ-CSP-vaccinated animals induced higher in vivo sporozoite neutralization activity.
Conclusions: Despite some immunologic parallels between models, these data demonstrate that differences 
between the immune responses induced in the two models risk conflicting decisions regarding potential vaccine 
utility in humans. In combination with historical observations, the data presented here suggest that although murine 
models may be useful for some purposes, non-human primate models may be more likely to predict the human 
response to investigational vaccines.
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Background
Malaria remains a major health concern in the tropics 
despite control efforts using available drugs and insecti-
cides. There is a broad consensus that a highly effective 
vaccine is needed. Two vaccines developed by Sanaria® 
(PfSPZ) and GlaxoSmithKline Vaccines (RTS,S), have 
demonstrated the proof-of-concept that a vaccine can 
protect against controlled human malaria infection 
(CHMI) [1]. Both PfSPZ and RTS,S vaccines induce 
potent immune responses against Plasmodium sporozo-
ites, in particular against the circumsporozoite protein 
(CSP). Efforts are underway to improve upon the success 
of PfSPZ and RTS,S, but there is considerable debate on 
what animal model should be used as the critical path 
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for advancing novel vaccine candidates to human tri-
als. The rodent model for malaria is based on Plasmo-
dium berghei, Plasmodium chabaudi or Plasmodium 
yoelii parasites that naturally infect African thicket rats 
[2]. These parasites have been adapted to grow in mouse 
strains for routine laboratory experiments and provide 
easy access to blood and liver stages. Rodent models have 
led to successful translation of many malaria drugs, how-
ever the down-selection of vaccines using mice has had 
mixed benefits. While the irradiated sporozoite vaccine 
can protect both rodents and humans [3], many sub-unit 
vaccines have failed to translate protection from mice 
to humans. A CSP DNA vaccine can induce very potent 
sterilizing protection against P. berghei and P. yoelii in 
mice [4, 5], but PfCSP-based DNA vaccines did not pro-
tect humans [6]. Likewise, the P. yoelii merozoite surface 
protein-1 (MSP1) [7] and P. chabaudi apical membrane 
antigen-1 (AMA1) [8] candidates have been known to 
protect mice, but human-use formulations of PfMSP1 [9] 
and PfAMA1 [10] vaccines confer limited protection in 
humans.
A lack of translation of observations from mice to 
humans is not surprising given that the common ances-
tor of humans and mice lived  ~75 million years ago 
and significant differences in the invasion biology of 
rodent and human malaria parasites exist [11]. Rhesus 
macaques (Macaca mulatta) and humans share a more 
recent common ancestor that lived approximately 25 
million years ago [12], and several malaria parasites that 
naturally infect rhesus, such as Plasmodium knowlesi and 
Plasmodium cynomolgi, are human transmissible [13]. 
Rhesus challenge models can be used to evaluate vac-
cines that inhibit parasite growth in both the liver and 
blood, whereas human trials with such vaccines man-
date drug treatment immediately at the onset of blood-
stage patency [14]. P. cynomolgi parasite challenge in 
rhesus allows cross-species protection studies to be 
conducted on Plasmodium vivax vaccines [15], circum-
venting the need for a much more complex controlled P. 
vivax human challenge. Rhesus models have also been 
useful in testing novel concepts such as multivalent 
and whole parasite vaccines [16, 17]. There are several 
instances where the rhesus model has predicted the suc-
cess of human malaria vaccine trials. The rationale for 
selection of the AS01 over AS02 adjuvant for the RTS,S 
vaccine was based on a rhesus trial [18] that was subse-
quently corroborated by CHMI and in the field [19, 20]. 
In another study, the adenovirus serotype-35 CSP prime 
and RTS,S boost improved the IFN-γ+ T cell responses 
in rhesus, but also showed lower antibody titres than 
RTS,S alone [21]. These findings were closely replicated 
in humans with improved T cell responses and reduced 
antibodies in the prime-boost arm [22]. In addition, the 
irradiated P. knowlesi sporozoite vaccine protected rhe-
sus against virulent P. knowlesi challenge and CD8+ T cell 
responses correlated with protection [23]; this has been 
replicated in CHMI model where irradiated Plasmodium 
falciparum sporozoite vaccine elicited protection was 
also characterized by induction of CD8+ T cell responses 
[3, 24, 25]. The rhesus model has not only predicted 
the success but also the failure of many experimental 
malaria vaccines. Formulations of PfMSP1 and PfAMA1 
that induced low level in vitro merozoite growth inhibi-
tion activity in the rhesus model [26] failed to protect 
humans [9, 10]. Soluble PvCSP that induced relatively 
low repeat specific antibodies in rhesus [27] also failed 
to confer sterile protection against PvCHMI [28]. These 
studies provide direct evidence that rhesus can accurately 
predict the immunogenicity and protection outcomes of 
experimental human malaria vaccines.
Despite excellent predictive capability, the scarcity and 
cost associated with non-human primates remain prob-
lematic and although rhesus malaria parasites are human 
transmissible, both P. falciparum and P. vivax cannot 
infect rhesus and hence direct challenge experiments are 
not feasible. A way to overcome the species barrier is to 
develop transgenic parasites. While transgenic rhesus 
parasites have been difficult to produce and select, trans-
genic rodent parasites carrying P. falciparum and P. vivax 
antigen genes are now routinely used to answer biologi-
cal questions [29, 30]. Mouse-human chimeric parasites 
expressing PfCSP, Pfs25, PfMSP1, and PvCSP have been 
used to compare the efficacy of human P. falciparum and 
P. vivax vaccines in mice [31–41]. In particular, trans-
genic parasites have been very useful to study the role 
of PfCSP during hepatocyte invasion [42, 43] and chal-
lenge models have been optimized to down-select PfCSP 
vaccines using P. berghei parasites that carry functional 
PfCSP genes [44, 45]. Considering previous examples 
where mouse data have not translated to protection in 
humans, there remains an uncertainty in the validity of 
using a mouse model for down-selecting P. falciparum 
and P. vivax malaria vaccines prior to CHMI. To address 
this issue, immunological responses to two vaccines were 
compared here in mice and rhesus.
The vaccines tested were derived from a nearly full-
length PfCSP construct expressed in Escherichia coli 
that contains the N-terminal region, 19 NANP, and three 
NVDP repeats followed by the C-terminal region. Also 
contained within the protein sequence were two inter-
species conserved motifs of PfCSP: ‘region I’ (located just 
before the central repeats) and the cysteine-rich ‘region 
II’ (located after the repeats). Both of these conserved 
regions have been implicated in hepatocyte invasion [42, 
46]. In order to produce a comparator particulate vac-
cine, the soluble CS protein was chemically coupled to 
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recombinant Qβ capsid protein. Qβ protein self-assem-
bles into 25 nm virus-like particles within E. coli cytosol 
and has been used as vaccine carrier in many human tri-
als [47–50]. During assembly in the cytosol, E. coli RNA 
is encapsulated inside the Qβ virus-like particles and this 
bacterial RNA serves as a potent adjuvant since it is a 
strong TLR7/8 agonist [51, 52]. It was recently reported 
that soluble CSP chemically conjugated to Qβ particles 
(Qβ-CSP) induced superior immunogenicity and efficacy 
compared to soluble CSP in several adjuvants in mice 
[53]. In the current study, the Qβ-CSP and soluble CSP 
vaccines were adjuvanted in Alum and used to immunize 
mice and rhesus. Although human data on these vaccine 
formulations are not available, rhesus responses were 
treated as a close surrogate for human responses based 
on their proven predictive value in previous malaria vac-
cine trials. Qβ-CSP generally induced higher overall anti-
body responses than CSP in both mice and rhesus, but 
differences in epitope specificity, avidity and functional-
ity of antibodies observed between the two species argue 
that rhesus ought to remain the choice model for the final 
down-selection step before advancing to human trials.
Methods
Vaccine antigens
CSP expression and purification has been reported previ-
ously [45]. The conjugation of CSP to Qβ phage particle 
was carried out using a cysteine-based cross-linker and 
has been described earlier [53]. The CSP content of the 
Qβ-CSP vaccine was determined as the sum of conjugated 
and unconjugated CSP to ensure the CSP content was 
equal in all comparator vaccine groups. Method of quan-
tifying CSP in Qβ-CSP has been previously described [53].
Animals
Six- to eight-weeks old female C57Bl/6 mice (Mus mus-
culus) supplied by Jackson Laboratory (Bar Harbor, ME, 
USA) were housed at the Walter Reed Army Institute 
of Research (WRAIR) animal facility for the duration of 
the study (IACUC-approved protocol number 11-MVD-
15). The room was maintained at 21–23 °C, with a rela-
tive humidity of 3–70%, 1–15 air changes hourly and a 
12:12-h light:dark cycle. At the time of this study, all mice 
were negative for Ectromelia virus, Mouse Cytomeg-
alovirus (MCMV), Mouse Parvovirus (MPV), Murine 
Norovirus (MNV), Mouse Adenovirus (MAdV-1/
MAdV-2), Polyomavirus, Lymphocytic Choriomeningitis 
Virus (LCMV), Sendai virus, Pneumonia Virus of Mice 
(PVM), Reovirus 1,2, and 3, Rotavirus, Mouse Hepatitis 
Virus (MHV), Theiler’s Murine Encephalomyelitis Virus, 
Mycoplasma pulmonis, CAR bacillus, Clostridium pili-
forme (Tyzzer’s Disease), and Helicobacter. Mice were 
singly housed in suspended, polycarbonate shoebox-type 
cages with filter tops on Beta Chip bedding Q3 (North-
eastern Products Corp, Warrensburg, NY, USA), and 
each cage had shreddable Q4 nesting material (Nestlets, 
Ancare, Bellmore, NY, USA) and an Igloo or similar tube 
for enrichment. Mice were fed a Q4 pelleted rodent food 
(RMH3000, Lab Diet, St Louis, MO, USA) and provided 
drinking water ad libitum. Sentinel mice used to monitor 
the health status of the experimental animals tested nega-
tive for all monitored pathogens.
Adult male rhesus macaques of Indian origin (M. 
mulatta), 9–15  years old and 6–15  kg weight were 
housed at the WRAIR animal facility and used under 
an IACUC-approved protocol, number 13-MVD-12L. 
Monkeys used were malaria naïve as assessed by ELISA 
against CSP antigen, but were used in other non-malaria 
studies in the past. The environment was maintained at 
20–22 °C, with a relative humidity of 30–70%, 10–15 air 
changes hourly and a 12:12-h light:dark cycle. All animals 
were free from overt clinical signs of illness, deemed to 
be in good health and tested negative for Macacine her-
pesvirus 1, measles, Simian Retrovirus, Simian Immuno-
deficiency Virus and Simian T-cell Leukemia Virus, and 
tuberculin skin test. Animals were singly housed, fed 
a commercial diet (Lab Diet 5038, Purina Mills Inter-
national, Brentwood, MO, USA) and provided water 
ad  libitum. Environmental enrichment was provided in 
accordance with WRAIR Veterinary Service Programs 
standing operating procedures.
Mouse vaccination, bleed and challenge
To determine optimal group size, ELISA titres follow-
ing three doses of a different CSP-based vaccine were 
log transformed and the standard deviation fed into the 
Russ Lenth online power calculator using the 2-sample 
t test algorithm [54]. The above calculation showed that 
n = 7 per group would have 80% power to discern ~two-
fold differences in mean titre. Mice (n  =  7 per group) 
received three doses of 2.5 µg CSP at 3-week intervals as 
soluble protein or Qβ-CSP formulated in Alum (300 µg/
ml aluminum content; Alhydrogel; Brenntag Biosector, 
Frederikssund, Denmark). Alum was mixed 1:1 v/v with 
the antigen by medium vortexing for 3  s every 5  min 
for 30  min and 100  µl of this vaccine was administered 
via 50 µl intra-muscular injection into each of the thigh 
muscles. The antigen dose and vaccine schedule were 
the same as has been previously used to differentiate 
between formulations as it gives sub-saturating levels of 
protection against this specific transgenic parasite strain 
[44, 45, 53]. Mice were bled at 3 weeks after each immu-
nization, except for the final bleed that was collected at 2 
weeks after the last dose. To measure protective efficacy, 
all mice were challenged with 3000 transgenic P. berghei 
sporozoites expressing a functional copy of the PfCSP 
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gene at 2 weeks after the last dose, as described previ-
ously [42, 44]. Briefly, sporozoites were collected using 
the Ozaki method [55] and injected into the lateral tail 
vein of mice. Mice were monitored daily and parasitaemia 
was detected using thin blood smears beginning at day 4 
post-challenge. Blood smears were fixed and stained with 
Giemsa. Mice found to be parasitaemic for 2 consecutive 
days were sacrificed and recorded as ‘not protected’ while 
mice that did not develop blood stage parasitaemia up to 
14 days post-challenge were reported as ‘protected’.
Rhesus vaccination and bleeds
Optimal group size was determined as above and n  =  5 
was shown to have 98% power to discern a two-fold differ-
ence in mean titre. Rhesus monkeys (n = 5 per group) were 
anaesthetized and the thigh area was shaved. A total 0.5 ml 
of the vaccine was administered intra-muscularly in the 
outer thigh muscle. Each vaccination contained 25 µg CSP 
or Qβ-CSP in Alum (300  µg/ml aluminum content). The 
schedule for vaccination was at 0, 1 and 3 months. Rhesus 
were bled 2 weeks after each vaccination for serology. The 
antigen dose for rhesus was chosen based on the proposed 
human dose of this vaccine, which is ten-fold higher than 
that used in the mouse model. The vaccine schedule was 
based on a previous publication on a rhesus monkey trial 
with RTS,S and an adenovirus-based CSP vaccine [21].
ELISA
ELISA plates (Immulon 2HB) were coated overnight at 
4  °C with either the full-length CSP antigen (FL, 50 ng/
well), the repeat peptide ((NANP)6C peptide at 20  ng/
well) or a recombinant protein encoding the C-terminal 
region of CSP (50  ng/well) essentially as described pre-
viously [44]. The secondary antibody used for the mouse 
and rhesus ELISA were HRP-conjugated anti-mouse or 
anti-rhesus IgG, respectively (Southern Biotech, Bir-
mingham, AL, USA). Horse Radish Peroxidase labelled 
secondary antibodies against Rhesus IgG1 (clone 7H11), 
IgG2 (clone 3C10) and IgG3 (2G11) were obtained from 
the NIH Non-human Primate Reagent Resource. The 
antibody titre was calculated as the serum dilution that 
produced an absorbance of 1.0 optical density (OD) 
units using Gen5™ software (Biotek). To measure avid-
ity, the above ELISA protocol was modified with an 
additional 6  M urea incubation step for 10  min follow-
ing the primary antibody incubation. Equal volume of 
phosphate buffered saline (PBS) was added for a con-
trol. Avidity index was defined as the titre (OD  =  1.0) 
in the presence of urea divided by the titre in the 
PBS control. Epitope specific ELISA was done using 
the following peptides—NT: DNAGTNLYNELEM-
NYYGKQENWYS; RI  +  repeat: KLKQPADGNPDP-
NANPNVDPNANPNVDPNANPNVDPNANP and RII: 
WSPCSVTCGNGIQVRIKPGSANKPKDELDYANDIEK-
KICKMEKCSS. All peptides were coated at 200 ng/well 
and 1:100 serum dilution was added to the well for 1 h. 
The reaction was developed as above and OD at 415 nm 
was recorded.
Competitive ELISA
Monoclonal antibodies 2A10 and 5D5 were obtained from 
the Malaria Research and Reference Reagent Resource 
Center MR4 (BEI Resources, Manassas, VA, USA). To 
determine the ability of polyclonal serum to block the 
binding of CSP-specific monoclonal antibodies (mAb), a 
competitive ELISA was developed. In brief, ELISA plates 
were coated overnight at 4 °C with FL antigen (15 ng/well) 
and then washed with PBS + Tween. Non-specific binding 
was blocked with PBS + 1% albumin for 1 h at room tem-
perature (RT) and then washed. Seventy-five microliter/
well of serially diluted (two-fold) mouse or rhesus serum 
was added to the plate and incubated for 1  h at RT. The 
mAbs were labelled with HRP using Lightning-Link HRP 
conjugation kit (Novus Biologicals, Littleton, CO, USA). 
Seventy-five microliter (~15 ng) of HRP-conjugated N-ter-
minal mAb 5D5 [56], C-terminal mAb 2F12 [53] or NANP 
mAb 2A10 [57] was then added directly to the wells and 
incubated for 1  h at RT. Plates were then washed and 
developed by the addition of 50  µl/well of ABTS peroxi-
dase substrate system (KPL) for 1 h at RT and stopped by 
adding 50 µl of 5% SDS. Absorbance was read at 415 nm 
on a microplate reader (Synergy 4, Biotek) using Gen5™ 
software (Biotek).
Sporozoite neutralization assay
To assess in vivo protective efficacy of rhesus antibodies in 
mice, a sporozoite neutralization assay (SNA) was devel-
oped. In brief, 50 µl of untreated serum from individual rhe-
sus monkeys was incubated for 10 min with 50 µl of RPMI 
containing 3000 transgenic P. berghei sporozoites. Mice were 
then challenged intravenously with 100 µl of the serum/
sporozoites mixture. Pre-immune rhesus serum from each 
of the test monkeys was used as a control. After challenge, 
mice were monitored for parasitaemia as described above.
Statistical analysis
Graphs show individual data points and/or the 
mean ±  SEM (geometric mean for graphs representing 
titres) of each group. In all cases, a P value of <0.05 was 
considered significant, as determined by an unpaired 
two-tailed t test comparing the soluble and particulate 
platforms to each other within the species. Statistically 
significant difference in group means was indicated as * 
(P < 0.05), ** (P < 0.01), *** (P < 0.001) or **** (P < 0.0001). 
Graphs were plotted and statistics were assessed by using 
GraphPad Prism software (La Jolla, CA, USA).
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Results
Qβ‑CSP analysis and vaccination
Qβ-CSP vaccine was prepared as previously described 
[53] and analysed by SDS-PAGE. Figure 1 shows that CSP 
and the Qβ proteins were highly pure and both migrated 
as a single band on reducing SDS-PAGE. Following con-
jugation of CSP and Qβ, multiple bands were detectable 
(Qβ-CSP lane). A  ~45  kDa band corresponded to free 
CSP (black arrow),  ~15  kDa band corresponded to the 
Qβ monomer (red arrow) and ~55 kDa band (blue arrow) 
corresponded to the conjugated Qβ-CSP molecule. 
Bands above 55 kDa in the Qβ-CSP lane corresponded to 
a CSP molecule linked to Qβ multimers that were gen-
erated during the cysteine-coupling reaction. Densito-
metric quantification of conjugation revealed that 19% of 
Qβ monomers had a CSP molecule conjugated to them. 
Hence, 34 CSP molecules were conjugated to an assem-
bled Qβ particle that is composed of 180 Qβ monomers 
[58]. To be able to compare the two vaccines, identical 
amounts of CSP were administered. For the Qβ-CSP vac-
cine conjugated and free CSP in the preparation were 
quantified as previously described [53]. The animal stud-
ies were based on previously published reports of CSP 
vaccine selection in mice [45] and in rhesus [21]. Mice 
received three vaccinations of 2.5 µg CSP at week 0, 3 and 
6 and rhesus received three vaccinations of 25  µg CSP 
(expected human dose) at month 0, 1 and 3.
Kinetics of antibody response
Comparing the trend of antibody titres over three immu-
nizations, mice (Fig. 2, coloured lines) showed a clearer 
separation between the Qβ-CSP (green) and CSP (red) 
vaccine induced FL, NANP and C-term titres as com-
pared to rhesus (black lines). In both models Qβ-CSP 
showed higher responses than CSP after the first dose, 
however, mice and rhesus differed substantially in the 
response to booster vaccines. In mice, successive doses of 
Qβ-CSP and CSP boosted titres but little or no boosting 
was observed beyond the second dose in rhesus. Indeed, 
no boosting of NANP titres were observed in rhesus after 
the first dose of Qβ-CSP, while in mice boosting post-sec-
ond and post-third was observed.
Both models agreed that FL, NANP and C-terminus 
titres were higher for the Qβ-CSP vaccine than CSP fol-
lowing the first vaccination (Table 1), but the magnitude 
Fig. 1 Purity of CSP, Qβ protein and conjugate Qβ-CSP. A range 
of CSP (black arrow, ~45 kDa) and Qβ protein (red arrow, ~15 kDa) 
amounts were run on reducing SDS-PAGE; loaded amounts are noted 
above each well. Conjugated Qβ-CSP (15 µl) was loaded in the last 
lane. Gel stained with Coomassie blue. Bands migrating at ~55 kDa 
and above (blue arrow) correspond to Qβ-CSP conjugate(s)
Fig. 2 Immunogenicity of CSP and Qβ-CSP in mice and rhesus. ELISA results against (a) FL antigen, (b) NANP repeat or (c) C-terminus for serum col-
lected 2–3 weeks after each immunization with CSP (solid symbols) or Qβ-CSP (open symbols). Plotted are group geometric mean antibody titre for 
mice (coloured lines, red or green, n = 7) and rhesus (black lines, n = 5). Fold increase of Qβ-CSP relative to CSP at each time-point is shown in Table 1
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of the difference between vaccines was maximal for the 
NANP epitope in mice. The NANP titre for the Qβ-CSP 
was >900-fold higher than CSP in mice, but only 12-fold 
higher in rhesus (Table  1). In mice, the Qβ-CSP main-
tained a clear immunological edge over CSP after the 
second dose with statistically significant differences in 
FL and NANP titres. In contrast, the differences between 
the two vaccines after the second dose were less clear in 
rhesus (Table 1). The immunogenicity difference between 
the two vaccines was further reduced in both models 
after the third dose, but mice continued to show sig-
nificantly higher FL and NANP response in the Qβ-CSP 
group. In rhesus, the NANP titre of the Qβ-CSP vaccine 
group was ~2.4-fold higher than CSP, however this differ-
ence was not statistically significant.
Avidity and subtypes
Avidity and IgG subtypes were measured against FL anti-
gen post third immunization. In mice, Qβ-CSP generated 
significantly higher avidity antibodies relative to CSP, 
while no avidity differences between the two vaccines 
were detectable in rhesus after the third dose (Fig. 3). As 
was previously reported [53], higher levels of IgG2c were 
induced by the Qβ-CSP vaccine compared to the CSP 
vaccine (data not shown); however, attempts to meas-
ure sub-classes in rhesus using either rhesus-specific or 
human-specific secondary antibodies were unsuccess-
ful as only the IgG1 antibody (rhesus or human) reacted 
with rhesus serum.
Region‑specific bias
Difference in antibody bias towards specific regions of the 
vaccine molecule was determined by normalizing indi-
vidual NANP and C-term titres by the respective FL titre. 
The NANP bias of Qβ-CSP antibodies was greater than 
CSP antibodies (NANP:FL titre ratio  >2) following the 
first and second vaccination in mice (Fig. 4a). Even after 
the third dose, a notable NANP bias was observed for 
Qβ-CSP in mice, although this was not statistically sig-
nificant compared to CSP. The higher level of NANP bias 
induced by Qβ-CSP was replicated in rhesus (NANP:FL 
titre ratio  ~2) (Fig.  4c), albeit only after the first dose. 
Mice and rhesus displayed no difference in C-terminus 
bias between the two vaccines (Fig. 4b, d).
Epitope‑specificity
To assess the relative abundance of antibodies against 
CSP epitopes, post-third vaccination sera were analysed 
by a direct peptide ELISA and a monoclonal antibody 
competition ELISA. The ‘NT’ peptide corresponded to 
a sequence in the N-terminus, the ‘RI +  repeat’ peptide 
was based on the conserved region-I and NVDPNANP 
repeat sequence, and the ‘RII’ peptide corresponded to 
the cysteine-rich region-II within the C-terminus. Mouse 
sera raised against Qβ-CSP vaccine contained higher 
levels of NT peptide-reacting antibodies than CSP vac-
cine sera; in contrast, the corresponding rhesus sera 
showed little NT peptide reactivity (Fig. 5a, b). Mice also 
showed a higher R1 +  repeat and RII peptide response 
in favour of Qβ-CSP vaccine after the third dose (Fig. 5a, 
b), while only the RII peptide ELISA showed a significant 
Table 1 Relative enhancement of CSP titres by conjugation to Qβ
CSP titre ratios of group geometric mean antibody titre for mice (n = 7) and rhesus (n = 5) 2–3 weeks after each immunization. ELISA was run against FL, NANP, and 
C-terminus plate antigens. Significant differences between log-transformed CSP and Qβ-CSP titres at each time point for each plate antigen was determined by two-
tailed t test, denoted by * (P < 0.05), ** (P < 0.01), *** (P < 0.001) or **** (P < 0.0001)
Mouse Rhesus
(Qβ‑CSP: CSP titre ratio) (Qβ‑CSP: CSP titre ratio)
FL NANP C‑term FL NANP C‑term
Post 1 3.3** 930**** 8.8** 4.1 12* 5.1*
Post 2 2.4** 10*** 1.8 1.2 2.4 2.2*
Post 3 2.5* 2.9* 2.5 1.3 2.4 1.4
Fig. 3 Serum antibody avidity against FL antigen. Avidity index for 
mice (solid points, n = 7) and rhesus (open points, n = 5) was calcu-
lated as the titre (OD = 1.0) in the presence of urea as a percentage of 
the titre in the PBS control. Bars represent mean avidity index ± SEM 
against FL antigen at 2 weeks post-third vaccination. P values are 
shown for statistically significant differences between CSP and 
Qβ-CSP determined by two-tailed t test
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difference between the two vaccines in rhesus. The ability 
of post-third mouse and rhesus serum to inhibit binding 
of mAbs to the FL antigen was also tested in a competi-
tion ELISA (Fig. 5c, d). Mouse antibodies showed that the 
Qβ-CSP vaccine induced higher N-terminus (mAb 5D5) 
and NANP repeat (mAb 2A10)-specific binding inhibi-
tion relative to the CSP vaccine (Fig.  5c). Rhesus anti-
bodies, however, failed to discern any difference between 
the two vaccines using this competition ELISA (Fig. 5d). 
Increased mAb 5D5 inhibition (Fig.  5c) by Qβ-CSP 
mouse sera correlated with the higher NT peptide ELISA 
responses (Fig. 5a). Overall, more epitope-specific differ-
ences between Qβ-CSP versus soluble CSP were seen in 
mice than in rhesus.
Protection
To evaluate the protective efficacy of the CSP and 
Qβ-CSP vaccines in mice, a transgenic P. berghei sporo-
zoite line that expressed the full-length CSP gene of P. 
falciparum was used to infect the mice 2 weeks after the 
third vaccine dose. All control mice became infected by 
day 7 and there was no significant difference in the level 
of protection induced by the CSP and Qβ-CSP vaccines 
(4/7 versus 5/7; Fig. 6a), even though the FL and NANP 
titres of the two groups were significantly different. Since 
no transgenic parasites for rhesus challenge were avail-
able, individual rhesus sera were tested using an in vivo 
SNA in the mouse transgenic parasite challenge model. 
All mice representing individual rhesus pre-immune sera 
were infected by day 5, but rhesus sera from 4/5 Qβ-CSP 
group monkeys showed protection while only 1/5 rhesus 
sera in the CSP group conferred protection (Fig. 6b). The 
higher protection in the Qβ-CSP group SNA was loosely 
associated with a higher titre (although not significant) 
and smaller spread of NANP repeat antibodies (Fig. 6b).
Discussion
A comparison of two malaria vaccines was conducted to 
determine if mice and rhesus models provided congru-
ent antibody read-outs. While there were differences in 
vaccine schedule and vaccine dose between species, the 
two models agreed on several immunologic outcomes: 
(1) Qβ-CSP vaccine had overall higher immunogenicity; 
(2) within the CSP molecule, the relative immunogenic-
ity of the repeat NANP epitope was specifically improved 
by particulate presentation on Qβ; and, (3) Qβ-CSP was 
better at priming antibody responses, but soluble CSP 
was able to boost antibody levels after subsequent doses, 
particularly against the NANP repeat. Apart from the 
similarities, the mouse and rhesus models differed from 
each other in the magnitude, kinetics, epitope breath 
and functionality of antibodies, summarized in Table  2. 
In general, more immunological differences between 
Qβ-CSP and CSP vaccines were detected in mice. The 
rhesus model revealed a key difference in functional 
activity of antibodies induced by the two vaccines using 
a SNA while mice failed to discern this difference upon 
direct challenge.
Mouse models are being used at an increasing rate to 
down-select second-generation malaria vaccines, but it 
would be costly to ignore preceding investigations where 
mouse data did not necessarily translate to humans. To 
the authors’ knowledge, this is the first report where iden-
tical malaria vaccine formulations have been compared 
in C57BL/6 mice and rhesus, both of which are com-
monly used models in malaria vaccine development. The 
main difference between the CSP and Qβ-CSP vaccines 
was the enhanced immunogenicity of Qβ-CSP, which 
could have resulted from its particulate nature and/or the 
TLR7/8 agonist activity of the entrapped RNA [59, 60]. 
Others have also reported that PfCSP antibodies can be 
readily boosted by a third immunization in mice while 
no additional boosting beyond the second vaccination 
was observed in rhesus [18, 26, 34, 61]. Not surprisingly, 
the boosting pattern of RTS,S in humans is similar to 
the rhesus after the second dose [62]. Overall, compared 
to rhesus, mice greatly amplified the immunogenicity 
Fig. 4 Relative immunogenicity of the NANP repeat and C-terminus 
regions of CSP. Data are expressed as the mean titre ratio (bars) ± SEM 
(whiskers) for mice (a, b; n = 7) and rhesus (c, d; n = 5) of NANP 
repeat titres (a, c) or C-terminus titres (b, d) to their respective FL 
antigen ELISA titre at post-first (P1), post-second (P2) and post-third 
(P3) vaccination with either CSP (solid bars) or Qβ-CSP (open bars). P 
values are shown for statistically significant differences between CSP 
and Qβ-CSP determined by two-tailed t tests
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differences between soluble CSP and Qβ-CSP, and this 
may reflect differences in the innate immune response 
pathways of the two species as was observed using a CpG 
oligodeoxynucleotide adjuvant for a Leishmania vaccine 
[63]. Furthermore, monkeys harbour much more genetic 
and epigenetic variability stemming from differences in 
individual age, microbiome and physiology, while the 
impact of these factors on immunogenicity is largely sup-
pressed in inbred mouse strains.
Despite the relatively low immunogenicity of soluble 
CSP in Alum, mice were protected in a direct challenge 
experiment. While reasons remain unclear, high-level 
protection with Alum-adjuvanted soluble CSP has been 
reported previously in mice [53], but it is also known that 
Alum-adjuvanted CSP vaccines do not induce significant 
protection in humans [64–67]. A similar observation has 
been made in influenza where several Alum-adjuvanted 
vaccines that induce protective levels of haemagglutinin 
response in mice do not protect humans [49, 68]. Using 
a functional SNA, rhesus revealed that Qβ-CSP + Alum 
was more protective than CSP + Alum. This functional 
activity was loosely associated with the magnitude and 
spread of NANP titres that also happen to be the best 
correlate of protection for CSP-based malaria vaccines in 
CHMI [69]. A recent report has suggested that antibodies 
against the N-terminus of CSP may offer additional pro-
tection, as they can block a proteolytic processing step 
during sporozoite invasion [56]. In mice, the Qβ-CSP 
induced higher N-terminal responses than CSP, but 
there was no difference in rhesus. These data highlight 
Fig. 5 Region- and epitope-specific responses. a, b Points represent optical density from a peptide ELISA at 1:100 serum dilution. Peptides com-
prised of the N-terminus (NT), conserved region I plus NVDPNANP repeats region (RI + repeat), and the cysteine rich region II of C-terminus (RII). c, 
d Points represent per cent inhibition of HRP-labelled 5D5 (N-terminus), 2A10 (NANP repeat) or 2F12 (C-terminus) mAb in the presence of individual 
sera. Inhibition is expressed as the percent decrease in optical density obtained by ELISA with mAb alone. Bars represent group means and whiskers 
represent standard error of the mean (SEM) for mouse (n = 5) and rhesus (n = 7) serum from 2 weeks post-third vaccination. P values are shown for 
statistically significant differences between CSP and Qβ-CSP determined by two-tailed t tests
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a fundamental problem with down-selecting human 
vaccines in mice and cautions against over-interpreting 
mouse vaccine data that show enhanced epitope-specific 
responses, enhanced avidity or even enhanced protec-
tion, as these results may not translate to higher mamma-
lian species. Rhesus on the other hand are not ideal for 
mechanistic studies in immunology as attempts to sub-
class rhesus macaque IgG using available rhesus (NIH 
NHP Reagent Resource) or human-specific reagents were 
unsuccessful. Others have reported similar limitations 
of using human sub-class reagents to analyse rhesus IgG 
[70]. Rhesus produces three distinct IgG sub-classes, but 
there is a much greater diversity among rhesus Ig genes 
compared to humans [71] and the functional equivalency 
of rhesus and known human IgG sub-classes has not 
been established.
While it would be ideal to use rhesus as they best emu-
late the human host, mice continue to be the pre-eminent 
in vivo model for malaria vaccine work as evidenced by 
more than 1900 Pubmed hits compared to 148 on rhe-
sus malaria vaccine research. It was found that the mouse 
immune system can amplify small immunological differ-
ences between formulations. Mice are therefore useful 
for early decision-making where one formulation must 
be picked among many. It is important however that the 
selection criteria in mice be kept fairly stringent, such as 
using a sterile protection outcome and conservative sta-
tistical tests to minimize Type-1 error. In rhesus, a less 
obvious difference between formulations was seen. Care-
ful balance between sample size and study cost is there-
fore necessary to reduce the risk of a Type-2 error while 
down-selecting vaccines in rhesus. These data and past 
Fig. 6 Protection efficacy of CSP versus Qβ-CSP vaccination. Individual titres for mice (n = 7) and rhesus (n = 5) 2 weeks post-third vaccination. Red 
symbols represent (a) mice immunized and protected in direct challenge with 3000 transgenic P. berghei sporozoites (Tr-Pb) or (b) mice protected 
by challenge with 3000 Tr-Pb in SNA with rhesus serum. Blue numbers represent the number of protected mice out of the total. Bars represent group 
geometric mean. P values are shown for statistically significant differences between CSP and Qβ-CSP determined by two-tailed t tests
Table 2 Differences between mouse and rhesus models
Summary of observed differences between animal models in the present study, with respect to comparison between Qβ-CSP and CSP vaccines. Tables and Figures 
illustrating noted differences are referenced for each parameter
Parameter Mouse model Rhesus model
Priming vaccination (Table 1; Fig. 2) ~900-fold higher Qβ-CSP NANP titres after first dose ~12-fold difference between vaccines
Booster vaccination (Fig. 2) Titres were boosted by each vaccination No boosting beyond second dose
Immunogenicity (Table 1; Figs. 2, 6) Significantly higher FL and NANP titres for Qβ-CSP 
group after the third dose
Differences between vaccines was lower and not 
significant
Serum antibody avidity (Fig. 3) Higher avidity of Qβ-CSP group No difference in avidity
NANP epitope bias (Fig. 4) NANP-biased Qβ-CSP group response after each dose NANP-biased response of Qβ-CSP after 1st dose only
NANP mAb competition (Fig. 5) Higher mAb 2A10 inhibition by anti-Qβ-CSP No difference in mAb inhibition detected
N-terminal response (Fig. 5) Higher N-terminal response by Qβ-CSP No difference in N-terminal response
Functional assay (Fig. 6) No difference in protection observed after direct chal-
lenge
Qβ-CSP protected more mice in a neutralization assay
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limitations of mouse models suggest that non-human 
primate immunogenicity in combination with functional 
assays needs to be a preferred model for final down-
selection prior to clinical trials.
Conclusions
This report has direct implications for numerous ongoing 
efforts to down-select CSP-based malaria vaccine candi-
dates and cautions against the use of only murine models 
for final down-selection of potential vaccine candidates 
for human studies. The immunogenicity of two malaria 
vaccine candidates in mice and rhesus were compared 
and it was found that, while the two models shared some 
of the immunologic outcomes, there were key differences 
between them. Mice showed a clear immunologic supe-
riority of a particulate Qβ-CSP formulation over soluble 
CSP, while the difference in responses to the soluble and 
particulate antigens was muted in rhesus. With the caveat 
that these vaccines have not yet been tested in humans, 
this study suggests that there are limitations of reliance 
on data derived solely from the mouse model in predict-
ing the human response to investigational vaccines and 
underlines the likely superiority of the rhesus model in 
this context.
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